Literature DB >> 25579750

Analysis of hysterectomies for patients with uterine leiomyomas in China in 2010.

Yu Gu1, Lan Zhu2, Aimin Liu3, Jingran Ma4, Jinghe Lang1.   

Abstract

OBJECTIVE: To analyze surgical methods and medical costs for patients with uterine leiomyomas treated by hysterectomy in mainland China in 2010.
METHODS: In a cross-sectional study, data for patients hospitalized with uterine leiomyomas and treated with hysterectomy were obtained from pooled medical records of 3030 hospitals. Type of surgery was categorized into abdominal hysterectomy (AH), laparoscopic hysterectomy (LH), and total vaginal hysterectomy (TVH). Length of stay and medical costs were analyzed for each procedure and in four types of hospital.
RESULTS: Among 147 966 patients, 129 668 (87.6%) underwent AH, 9164 (6.2%) LH, and 9134 (6.2%) TVH. The total cost and operative cost were lowest for the AH group and highest for the LH group (P<0.001). Length of stay was shortest for TVH groups in all four types of hospital (P<0.001). The ratios between the frequencies of the three procedures were significantly different among the four types of hospital (P<0.001).
CONCLUSION: In mainland China, AH remains the main surgical route of hysterectomy for patients with uterine leiomyomas. The length of stay was shortest among patients undergoing TVH, but the mean stay was still more than 9days.
Copyright © 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hysterectomy; Surgery; Uterine leiomyoma

Mesh:

Year:  2014        PMID: 25579750     DOI: 10.1016/j.ijgo.2014.10.031

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  1 in total

1.  Cost effectiveness analysis of total laparoscopic hysterectomy versus total abdominal hysterectomy for uterine fibroids in Western China: a societal perspective.

Authors:  Jinjuan Yang; Xiaojing Fan; Jianmin Gao; Dan Li; Yongjian Xu; Gang Chen
Journal:  BMC Health Serv Res       Date:  2022-02-24       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.